This question reminds me of our experience when we experienced immunotherapy such as the bispecific for the first time like in four years ago. We were so afraid to manage CRS, how to recognize and how to treat, but through the years we have come to notice that with bispecific, especially those which we use for myeloma, CRS is not a big issue. You can treat them easily, and tocilizumab is a very helpful agent...
This question reminds me of our experience when we experienced immunotherapy such as the bispecific for the first time like in four years ago. We were so afraid to manage CRS, how to recognize and how to treat, but through the years we have come to notice that with bispecific, especially those which we use for myeloma, CRS is not a big issue. You can treat them easily, and tocilizumab is a very helpful agent. And nowadays, there is more data coming in to use tocilizumab preemptively to prevent hospitalization and to allow outpatient administration. So for community doctors, of course, this requires experience, but like everything else, when we start a new drug, the first steps are you need to be more cautious, more careful, but in time you learn. So it’s the learning curve that matters the most. And I’m sure community doctors will be able to handle this. And if they have the capacity to hospitalize patients, that’s okay. And the other thing which they have to be more alerted about is the rate of infections. And the use of intravenous immunoglobulin frequently, like with three to four weeks of intervals and taking care of the IgG level and also accounting for the clonal IgG and not to miss the real hypogammaglobulinemia. In that fashion, the rate of infections will be less, and use of routine antibiotics, especially the quinolone type of antibiotics, is becoming more widespread. So these are the major two issues that I think will be very helpful for those centers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.